Ontology highlight
ABSTRACT:
SUBMITTER: Crim C
PROVIDER: S-EPMC6413745 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature
Crim Courtney C Watkins Michael L ML Bateman Eric D ED Feldman Gregory J GJ Schenkenberger Isabelle I Kerwin Edward M EM Crawford Catriona C Pudi Krishna K Ho Shuyen S Baidoo Charlotte C Castro-Santamaria Ramiro R
International journal of chronic obstructive pulmonary disease 20190308
<h4>Background</h4>Batefenterol is a novel bifunctional muscarinic antagonist β<sub>2</sub>-agonist in development for COPD. The primary objective of this randomized, double-blind, placebo-controlled, active comparator, Phase IIb study was to model the dose-response of batefenterol and select a dose for Phase III development.<h4>Patients and methods</h4>Patients aged ≥40 years with COPD and FEV<sub>1</sub> ≥30% and ≤70% predicted normal were randomized equally to batefenterol 37.5, 75, 150, 300, ...[more]